GlassScriptPhysician profile
Ira M Sabbagh
NPI 1619978780
$4,202.58
in general payments reported to CMS, 2019-2025
34 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $444 · 2021: $660 · 2022: $662 · 2023: $543 · 2024: $507 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $457.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $456.00 | 2021-2025 | Ubrelvy, Qulipta |
| Allergan, INC. | $370.22 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $222.49 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Amgen INC. | $214.55 | 2020-2025 | Repatha, Evenity, Otezla |
| Radius Health, INC. | $195.43 | 2019-2024 | Tymlos |
| Janssen Pharmaceuticals, INC | $182.90 | 2020-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.90 | 2022-2025 | Caplyta |
| Genzyme Corporation | $125.00 | 2023 | |
| Ethicon US, LLC | $124.17 | 2019 | |
| Alkermes, INC. | $119.59 | 2021-2025 | Lybalvi |
| Pfizer INC. | $99.05 | 2019-2025 | |
| Lundbeck LLC | $94.44 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $94.34 | 2022-2025 | Airsupra, Farxiga |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.49 | 2021-2022 | |
| Glaxosmithkline, LLC. | $80.25 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Conmed Corporation | $73.30 | 2019 | |
| Intuitive Surgical, INC. | $73.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.85 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $59.53 | 2020-2022 | |
| Astellas Pharma US INC | $48.87 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.34 | 2024-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $32.05 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $30.66 | 2019 | |
| Biogen, INC. | $27.25 | 2025 | Skyclarys |
| Axsome Therapeutics, INC. | $23.21 | 2024 | Sunosi |
| Alvogen INC | $20.34 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.50 | 2019 | |
| Medtronic USA, INC. | $18.29 | 2019 | |
| Owp Pharmaceuticals, INC. | $17.55 | 2023 | Subvenite, Lamotrigine |
| Ironshore Pharmaceuticals INC. | $16.93 | 2019 | |
| Mylan Specialty L.P. | $13.18 | 2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Sabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.